Affordable Access

deepdyve-link
Publisher Website

Eplerenone for the treatment of chronic central serous chorioretinopathy: 3-year clinical experience.

Authors
  • Petkovsek, Daniel S1
  • Cherfan, Daniel G1
  • Conti, Felipe F1, 2
  • Hom, Grant L2
  • Ehlers, Justin P1
  • Babiuch, Amy S1
  • Rachitskaya, Aleksandra V1
  • Kaiser, Peter K1
  • Schachat, Andrew P1
  • Srivastava, Sunil K1
  • Sharma, Sumit3
  • Singh, Rishi P4
Type
Published Article
Journal
British Journal of Ophthalmology
Publisher
BMJ
Publication Date
May 10, 2019
Identifiers
DOI: 10.1136/bjophthalmol-2019-314047
PMID: 31079056
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

The efficacy of mineralocorticoid receptor antagonist eplerenone to treat chronic central serous chorioretinopathy (CSCR) has been established. However, previous studies have been limited by small cohort size and short follow-up duration. This study aims to report 3-year clinical outcomes of patients treated with eplerenone for chronic CSCR. Institutional review board-approved retrospective chart analysis at a single institution from 2012 to 2018. Baseline best-corrected visual acuity and anatomical measurements related to degree of subretinal fluid (SRF) were collected at eplerenone initiation. Follow-up data were collected at the closest date to 12, 24 and 36 months. Data were obtained for 100 eyes of 83 patients at 1-year (mean 11.18 ± 4.00 months), 49 eyes at 2-year (24.01 ± 3.33 months) and 33 eyes at 3-year (mean 35.5 ± 7.89 months) follow-up visits. The rate of complete SRF resolution was 31%, 28% and 33%, respectively. At final follow-up, logarithm of the minimum angle of resolution visual acuity change from baseline was +0.10 ± 0.24 (p = 0.130). Average change from baseline at final follow-up for central subfield thickness was -97 ± 140.6 µm (p < 0.001), cube volume was -1.07 ± 1.71 mm3 (p < 0.001), macular thickness -28. 5 ± 47.5 µm (p < 0.001), maximum SRF height was -95.6 ± 160.5 µm (p < 0.001) and maximum SRF diameter was -1169.0 ± 1638.7 µm (p = 0.008). Anatomical improvement occurs primarily within the first year of eplerenone treatment for chronic CSCR. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Report this publication

Statistics

Seen <100 times